Comparative Pharmacology
Head-to-head clinical analysis: DIATRIZOATE MEGLUMINE versus OMNIPAQUE 12.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIATRIZOATE MEGLUMINE versus OMNIPAQUE 12.
DIATRIZOATE MEGLUMINE vs OMNIPAQUE 12
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diatrizoate meglumine is an ionic, high-osmolar iodinated contrast agent that absorbs X-rays due to its iodine content, thereby enhancing radiographic imaging. It does not exert pharmacological effects via receptor interaction but functions by attenuating X-ray beams, providing contrast between vascular structures and surrounding tissues.
Radiopaque agent that attenuates X-rays, providing contrast in imaging. Iodine atoms absorb X-rays, enhancing visualization of blood vessels and tissues.
Intravenous: 1-2 mL/kg (305-610 mg I/kg) of 60% or 76% solution for urography; 40-60 mL of 50% solution for retrograde cystourethrography. Oral: 200-600 mL of 4.8% suspension for GI contrast.
Adult dose: 12 g iodine (e.g., 200 mL of Omnipaque 12) administered intravenously, intra-arterially, or into body cavities. Typical contrast study dose: 1-2 mL/kg (max 150 mL) for CT; 40-60 mL for angiographic procedures.
None Documented
None Documented
Terminal elimination half-life is approximately 1-2 hours in patients with normal renal function (CLcr >90 mL/min). Half-life is significantly prolonged in renal impairment (up to 20-40 hours in anuria), necessitating dose adjustment and caution.
1-2 hours (normal renal function); prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min)
Primarily renal excretion via glomerular filtration; >95% of the administered dose is excreted unchanged in urine within 24 hours. Less than 5% is excreted in feces via biliary elimination.
Renal: >95% unchanged; biliary/fecal: <5%
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent